This article reviews results from the REVEAL-HBV study, which found that hepatitis B virus DNA across a biologic gradient is very strongly predictive of the risk of disease progression and remains a strong predictor of risk after accounting for other important factors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cld.2007.08.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Viral Load-Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B : A Multinational Study for the Development and External Validation of a New Prognostic Model.
Ann Intern Med
October 2024
Academia Sinica, Taipei, Taiwan (C.-J.C.).
Article Synopsis
- - The study aimed to create and validate a prognostic model for assessing the risk of hepatocellular carcinoma (HCC) in noncirrhotic adults with chronic hepatitis B, focusing on those without significant alanine aminotransferase (ALT) elevation.
- - Researchers analyzed data from over 13,000 patients across several cohorts in Taiwan, Korea, and Hong Kong, finding that baseline HBV DNA levels were key predictors of HCC risk, especially at moderate viral loads.
- - The new model, called Revised REACH-B, showed strong predictive accuracy and was more beneficial compared to other strategies in predicting HCC risk, though its applicability to other racial groups remains a limitation.
Exposure to PM Metal Constituents and Liver Cancer Risk in REVEAL-HBV.
J Epidemiol
February 2024
Institute of Environmental and Occupational Health Sciences, National Yang Ming Chiao Tung University.
Background: Ambient particulate matter is classified as a human Class 1 carcinogen, and recent studies found a positive relationship between fine particulate matter (PM) and liver cancer. Nevertheless, little is known about which specific metal constituent contributes to the development of liver cancer.
Objective: To evaluate the association of long-term exposure to metal constituents in PM with the risk of liver cancer using a Taiwanese cohort study.
Biomarkers of gut barrier dysfunction and risk of hepatocellular carcinoma in the REVEAL-HBV and REVEAL-HCV cohort studies.
Int J Cancer
July 2023
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Article Synopsis
- Gut barrier dysfunction can expose the liver to harmful bacterial products, potentially leading to liver diseases like hepatitis and HCC.
- This study explored the link between gut barrier dysfunction biomarkers and HCC risk in individuals with hepatitis B or C, using data from Taiwanese cohorts (REVEAL-HBV and REVEAL-HCV).
- Results indicated that higher levels of specific biomarkers (like antiflagellin IgA and LBP) correlated with a significantly increased risk of developing HBV-related HCC, suggesting a connection between gut health and liver cancer.
Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines.
Hepatol Int
December 2021
Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, Republic of China.
Backgrounds: ALT ≥ 80 U/L and HBV DNA ≥ 2000 IU/ml are treatment criteria of APASL guidelines for chronic hepatitis B (CHB) patients. The need of antiviral therapy for patients in gray zone (ALT < 80 U/L or HBV DNA < 2000 IU/ml) is controversial. This study aimed to develop a scoring system to predict hepatocellular carcinoma (HCC) and evaluate the benefit of antiviral therapy in these patients.
View Article and Find Full Text PDFImmunologic markers and risk of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-infected individuals.
Aliment Pharmacol Ther
September 2021
Genomics Research Center, Academia Sinica, Taipei, Taiwan.
Background: Clinical and experimental studies suggest immunologic proteins contribute to hepatocellular carcinoma (HCC) development.
Aim: To evaluate circulating immunologic markers and HCC risk.
Methods: From a Taiwanese cohort of chronically hepatitis B virus (HBV)-infected individuals followed over time (REVEAL-HBV), we sampled 175 who developed HCC, 117 cirrhosis only, and 165 non-cirrhotic controls.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!